This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ (RIT 90YEpra)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2011 by Nantes University Hospital.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Nantes University Hospital Identifier:
First received: July 17, 2009
Last updated: June 24, 2014
Last verified: May 2011
The purpose of this study is to determine whether fractionated RIT with Epratuzumab and radiolabeled Epratuzumab are effective in the treatment of relapsing or refractory ALL.

Condition Intervention Phase
Acute Lymphoblastic Leukemia Drug: Epratuzumab and 90Y-Epratuzumab Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy and Tolerance of Fractionated Radio-immunotherapy With 90Y-Epratuzumab (90Y-hLL2) for Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukaemia Patients

Resource links provided by NLM:

Further study details as provided by Nantes University Hospital:

Primary Outcome Measures:
  • Determination of MTD by evaluation of hematological and non hematoligical toxicity
    The primary endpoint is to evaluate the incidence of dose limiting toxicities (DLT) in order to determine the maximal tolerated dose (MTD) in a dose escalating study design

Secondary Outcome Measures:
  • rate of haematological response
    To determine the hematologic response

Estimated Enrollment: 21
Study Start Date: November 2010
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Epratuzumab and 90Y-Epratuzumab
Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
Drug: Epratuzumab and 90Y-Epratuzumab
Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-70 years
  • B-ALL (OMS) with >=20% of blasts in bone marrow
  • CD22+ expression >=70% of the blast population
  • All previously treated ALL patients who have experienced relapse or treatment failure
  • At least 15 days since previous treatment
  • Performance status 0 - 2
  • Creatinine clearance >= 50 ml/min (Cockroft formula).
  • Serum bilirubin <= 30 mmol/l
  • Written informed consent

Exclusion Criteria:

  • T-ALL
  • Meningeal involvement
  • CD22 expression on tumor cells or < 70%
  • HIV positive
  • Active Hepatitis B or C
  • Active infection within 7 days of starting treatment
  • Left ventricular ejection fraction < 50%.
  • Contra-indication to 90Y-DOTA-hLL2
  • Previous or concurrent second malignancy except for adequately treated basal cell carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively treated solid cancer, with no evidence of disease for at least 5 years
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Participation at the same time in another study in which investigational drugs are used
  • Absence of written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01354457

CHU Nantes
Nantes, France, 44000
Sponsors and Collaborators
Nantes University Hospital
Principal Investigator: Chevallier Patrice, MD CHU Nantes
Principal Investigator: Kraeber-Bodere Françoise, MD CHU Nantes
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Nantes University Hospital Identifier: NCT01354457     History of Changes
Other Study ID Numbers: BRD 08/12-H
Study First Received: July 17, 2009
Last Updated: June 24, 2014

Keywords provided by Nantes University Hospital:
Patient with relapsing or refractory CD22+B-acute lymphoblastic leukemia (ALL)

Additional relevant MeSH terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 19, 2017